Humacyte Inc. Warrant (HUMAW)
$0.00
$0.00
(-78.05%)
As on 25-Aug-2026 15:59EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-352.98 Mln
EBITDA
$-524.57 Mln
Net Profit
$-163.17 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Humacyte Inc. Warrant (HUMAW)
| -99.0 | -91.0 | -98.9 | -99.5 | -89.8 | -78.8 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Humacyte Inc. Warrant (HUMAW)
| -94.9 | 332.4 | 5.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Humacyte Inc. Warrant (HUMAW)
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple... therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina. Read more
-
Founder, President, CEO & Director
Dr. Laura E. Niklason M.D., Ph.D.
-
Founder, President, CEO & Director
Dr. Laura E. Niklason M.D., Ph.D.
-
Headquarters
Durham, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Humacyte Inc. Warrant (HUMAW)
What is the current share price of Humacyte Inc Warrant (HUMAW) Today?
The share price of Humacyte Inc Warrant (HUMAW) is $0.00 (NASDAQ) as of 25-Aug-2026 15:59 EDT. Humacyte Inc Warrant (HUMAW) has given a return of -89.78% in the last 3 years.
What is the current PB & PE ratio of Humacyte Inc Warrant (HUMAW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.36 |
4.77 |
2024 |
-1.45 |
-4.09 |
2023 |
-0.39 |
3.18 |
2022 |
-3.38 |
0.35 |
2021 |
-9.02 |
1.95 |
What is the 52 Week High and Low of Humacyte Inc Warrant (HUMAW)?
The 52-week high and low of Humacyte Inc Warrant (HUMAW) are Rs 0.40 and Rs 0.00 as of 04-Sep-2026.
What is the market cap of Humacyte Inc Warrant (HUMAW)?
Humacyte Inc Warrant (HUMAW) has a market capitalisation of -- as on 25-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Humacyte Inc Warrant (HUMAW)?
Before investing in Humacyte Inc Warrant (HUMAW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.